Mon, April 1, 2024

Silvan Tuerkcan Reiterated (ACRV) at Buy and Held Target at $14 on, Apr 1st, 2024

Silvan Tuerkcan of JMP Securities, Reiterated "Acrivon Therapeutics, Inc." (ACRV) at Buy and Held Target at $14 on, Apr 1st, 2024.

Silvan has made no other calls on ACRV in the last 4 months.



There is 1 other peer that has a rating on ACRV. Out of the 1 peers that are also analyzing ACRV, 0 agree with Silvan's Rating of Hold.



This is the rating of the analyst that currently disagrees with Silvan


  • Emily Bodnar of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $20 on, Thursday, March 28th, 2024